Screen Shot 2022-03-24 at 10.54.04 PM

Medstream360 members only

To view this video and learn more about the procedure please Login or Register.
Membership is free!

The Mount Sinai Hospital

1468 Madison Avenue, New York,
New York 10029

Bioprosthetic Aortic ViV TAVR after Valve Fracture and Evolut Pro+ Implantation

TAVR valve-in-valve

60 year-old male presents with worsening exertional dyspnea (NYHA Class III) and multiple admissions for CHF exacerbation in past 3 months. Past medical history is significant for symptomatic severe aortic insufficiency s/p bioprosthetic AVR (2017) with 23mm Magna 3000 valve, ESRD on HD, HTN and HLD. Recent echocardiogram revealed bioprosthetic valve degeneration with severe aortic stenosis (PG/MG/AVA of 75/51/0.67) and depressed LVEF of 30%. Coronary angiogram showed moderate 2V CAD being medically managed. Lower extremities on CT angiogram revealed calcified arteries with vessel size > 6mm. The Internal diameter of surgical AV measured 21.5√ó22.3mm (mean 21.9mm), perimeter 68.3mm and the area 370.6 mm2. The STS mortality risk for surgical AVR was calculated at 5.83%. The patient underwent Heart Team evaluation and was found to be at high risk for re-do SAVR due to comorbidities and frailty. Now planned for Valve-in-Valve TAVR with 26mm Evolut Pro+ CoreValve and bioprosthetic valve fracture using 23mm True Balloon via right percutaneous femoral approach.

download

Case Presentation

close

Lorem ipsum dolor sit amet consectetur adipisicing elit. A, dignissimos?